• Carcinoma Squamoso Orofaringe
• chemio-radioterapia
• chirurgia robotica trans-orale
• HPV
• qualità della vita
• radioterapia
• sopravvivenza globale
• sopravvivenza libera da malattia

Background: Treatment de-intensification for p16+ oropharyngeal squamous cell carcinoma is an area of active research. The rationale for this is to reduce the side effects of these treatments and improve patients’ quality of life. In this paper we evaluated the Overall Survival, the Disease-Free Survival and the quality of life of patients affected by p16+ oropharyngeal squamous cell carcinomas according to their prognostic stage group and their different treatments.
Materials and Methods: Patients were selected retrospectively through our Electronic Tumor Board Database according to specific inclusion criteria. Basic data of eligible patients were recorded and analyzed. Then, the Overall Survival and the Disease-Free Survival were evaluated according to the prognostic stage group and the treatments performed. After that, the eligible patients completed three questionnaires: the Quality of Life Questionnaire Core 30 (QLQ-C30), the Quality of Life Questionnaire Head & Neck 43 (QLQ-HN43) and the MD Anderson Dysphagia Inventory (MDADI) questionnaire.
Results: 61 patients were included in this study. 8 patients died from the disease and the remaining 53 patients completed the 3 questionnaires. 15 (25%) patients were treated with surgery +/- adjuvant therapy, 6 (10%) patients with definitive radiotherapy and 40 (65%) patients with concomitant chemoradiotherapy. Comparing the DFS and the OS of PSG I patients by the different treatments performed, no statistically significant difference was identified. Patients treated with upfront surgery showed statistically significant better outcomes in some aspects of their quality of life.
Conclusion: For p16+ OPSCC PSG I patients, TORS with neck dissection plus/minus adjuvant treatment can be considered a valid alternative to radiotherapy or radiochemotherapy while maintaining a comparable DFS and OS and giving patients better results in terms of specific aspects of their QoL.